Ads
related to: merck- Contact Us
Get In Touch With Our Experts.
We Would Love to Hear From You.
- Development
Comprehensive Integrated Offerings
Bioavailability Enhanced Technology
- Oral Technologies
Proven Expertise Versatile Delivery
Seamless Scale-Up
- Clinical Manufacturing
Blinding & Clinical Manufacturing
Over-encapsulation & Masking
- Contact Us
thomasnet.com has been visited by 10K+ users in the past month
Search results
Merck to buy eye-focused drug developer EyeBio for as much as $3 bln
Reuters· 6 days agoThe deal is the latest in a string of recent acquisitions by Merck to reduce its reliance on...
Merck KGaA (MKGAF) Upgraded to Buy: Here's What You Should Know
Zacks· 6 days agoFree Report) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the ...
Moderna & Merck Announce 3-Year Data For mRNA-4157 (V940) in Combination With KEYTRUDA(R)...
Digital Journal· 1 day agoAt a median planned follow-up of the Phase 2b study at 34.9 months, mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 49% and the risk of distant metastasis ...
Merck acquires EyeBio in up to $3B deal By Proactive Investors
Investing.com· 6 days agoMerck & Co Inc (NYSE:MRK, ETR:6MK) announced it is acquiring Eyebio, a privately held...
Merck nears $1.3 billion cash deal for eye-drug company EyeBio, WSJ reports
AOL· 7 days agoMerck did not immediately respond to Reuters' request for a comment, while Eyebiotech declined to comment. Eyebiotech is a clinical stage opthalmology company, with operations ...
Merck's Multi-Billion Cancer Drug Keytruda Aces Late-Stage Breast Cancer Study (UPDATED)
Benzinga· 7 days agoEditor’s Note: The title of the story is updated to correct the reference to ‘Breast’ cancer instead...
Merck to acquire eye drug company EyeBio for up to $3 billion
WHTC 1450 Holland· 6 days ago(Reuters) - Merck said on Wednesday it would acquire eye disease drug developer EyeBio for up to $3...
Merck to acquire EyeBio in potential $3B deal
NJBIZ· 6 days agoOn Wednesday morning, Rahway-headquartered Merck announced it will acquire EyeBio in a deal that has a potential value of $3 billion. The agreement will bring EyeBio into ...
Merck’s KEYTRUDA shows survival benefits in Phase III TNBC trial
Clinical Trials Arena via Yahoo Finance· 6 days agoMerck has reported that its Phase III KEYNOTE-522 clinical trial of KEYTRUDA to treat high-risk,...
Pharma Stock Roundup: JNJ, MRK M&A Deals, SNY, RHHBY Drugs' Priority Review & More
Zacks via Yahoo Finance· 4 days agoJ&J (JNJ) and Merck (MRK) announce the acquisitions of private biotechs. The FDA grants Priority...